Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial

This publication has 21 references indexed in Scilit:

• Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age☆
  Vaccine, 2011
• Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old
  Vaccine, 2009
• Safety and Immunogenicity of a Baculovirus-Expressed Hemagglutinin Influenza Vaccine
  JAMA, 2007
• Dose‐Related Safety and Immunogenicity of a Trivalent Baculovirus‐Expressed Influenza‐Virus Hemagglutinin Vaccine in Elderly Adults
  The Journal of Infectious Diseases, 2006
• Symptomatic Pericarditis After Influenza Vaccination
  Chest, 2000
• Recombinant Baculovirus Influenza A Hemagglutinin Vaccines Are Well Tolerated and Immunogenic in Healthy Adults
  The Journal of Infectious Diseases, 1996
• Evaluation of a Recombinant Hemagglutinin Expressed in Insect Cells as an Influenza Vaccine in Young and Elderly Adults
  The Journal of Infectious Diseases, 1996
• Influenza A Virus Vaccines Containing Purified Recombinant H3 Hemagglutinin Are Well Tolerated and Induce Protective Immune Responses in Healthy Adults
  The Journal of Infectious Diseases, 1995
• Efficacy of Inactivated Influenza A Virus (H3N2) Vaccines Grown in Mammalian Cells or Embryonated Eggs
  The Journal of Infectious Diseases, 1989
• Influenza A (H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule
  Virology, 1989